N. Engl. J. Med.
Osimertinib in EGFR Mutation–Positive Advanced NSCLC.
Related Questions
Can SRS or whole brain radiotherapy be reserved for progression in these young, healthy patients?
New answer by Radiation Oncologist at Levine Cancer Institute (June 8, 2018)
I think the answers to this question above make some great points. However, old data on this topic are now a bit outdated with the recent results of the FLAURA trial which mov...